Harnessing Machine Vision Algorithms to Direct Car-T Cell Navigation Across Complex Tumor Landscapes in Next-Generation Immunotherapy

Trends in Immunotherapy

Article

Harnessing Machine Vision Algorithms to Direct Car-T Cell Navigation Across Complex Tumor Landscapes in Next-Generation Immunotherapy

Downloads

https://doi.org/10.54963/ti.v9i4.1289
K, J. R., Mythili, R., Vidhyasree, M., Kumar, S. S., Sagar, B. J. K., & K, I. A. J. (2025). Harnessing Machine Vision Algorithms to Direct Car-T Cell Navigation Across Complex Tumor Landscapes in Next-Generation Immunotherapy. Trends in Immunotherapy, 9(4), 86–103. https://doi.org/10.54963/ti.v9i4.1289
Volume 9 Issue 4 (December 2025): In Progress
Copyright (c) 2025 Jose Reena K, R. Mythili, M. Vidhyasree, S Saravana Kumar, B.J. Job Karuna Sagar, Immanuvel Arokia James K
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Jose Reena K

    Department of Computer Applications, B. S. Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai, Tamil Nadu 600048, India
  • R. Mythili

    Department of Information Technology, SRM Institute of Science and Technology, Ramapuram, Chennai, Tamil Nadu 600089, India
  • M. Vidhyasree

    Panimalar Engineering College, Nazarapet, Chennai, Tamilnadu 600123, India
  • S Saravana Kumar

    Department of CSE, PSCMR College of Engineering and Technology, Vijayawada, Andhra Pradesh 520001, India
  • B.J. Job Karuna Sagar

    Department of CSE, Joginpally B.R Engineering College, Hyderabad, Telangana 500075, India
  • Immanuvel Arokia James K

    Department of Artificial Intelligence and Data Science, Vel Tech Multi Tech Dr. Rangarajan Dr. Engineering College, Chennai, Tamil Nadu 600072, India

Received: 31 May 2025; Revised: 19 June 2025; Accepted: 27 June 2025; Published: 30 October 2025

In the immunotherapy process, a machine vision algorithm exhibits an efficient next-generation model for navigating the complex tumor microenvironment with CAR-T cells. With the integration of image-based analysis into the real-time processing algorithm, the system is able to compute spatial guidance for the immune cell, enabling it to detect, eliminate, and infiltrate cells. The variation between computational vision and cellular therapy needs to overcome the issues in the physical and biological barriers of tumors. Hence, in this paper, an effective Fejer Kernel Entropy Masked R-Convolutional Neural Network (FEM-R-CNN) was constructed. The proposed FEM-R-CNN model performs pre-processing of the CAR-T cell using the Fejer Kernel, and segmentation is performed with the entropy model. With the estimated segmentation, the Single Shot Detector (SSD) is employed for the CAR-T cell, and classification is computed using the masked R-CNN for the immunotherapy. Experimental results demonstrate that FEM-R-CNN achieves a cancer cell detection accuracy of 96.2%, a segmentation Intersection over Union (IoU) of 0.86, and a classification accuracy of 94.8%, outperforming traditional models such as U-Net and standard Mask R-CNN by over 5% across key metrics. The model improves signal-to-noise ratio by 46.4% and reduces false positive rates by 53.3%, enabling more precise CAR-T cell navigation. Immune response analysis revealed a CAR-T cell density of up to 150 cells/mm², with a 50% proliferation rate and 72% tumor cell apoptosis, indicating effective immune activity monitoring. The inference time remains competitive at approximately 70 ms per image, supporting near real-time applications.

Keywords:

Computer Vision Classification Segmentation Convolutional Neural Network (CNN) Immunotherapy

References

  1. Zhou, Z.; Wang, J.; Wang, J.; et al. Deciphering the Tumor Immune Microenvironment From a Multidimensional Omics Perspective: Insight Into Next-Generation CAR-T Cell Immunotherapy and Beyond. Mol. Cancer 2024, 23, 131.
  2. Srivastava, S.; Tyagi, A.; Pawar, V.A.; et al. Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies. Immunotargets Ther. 2024, 13, 413–433.
  3. Capponi, S.; Daniels, K.G. Harnessing the Power of Artificial Intelligence to Advance Cell Therapy. Immunol. Rev. 2023, 320, 147–165.
  4. Damane, B.P.; Mulaudzi, T.; Maphoso, T.; et al. Immunotherapy Advancements: Harnessing the Immune System With Technological Precision. In Navigating Melanoma Treatment Challenges, 1st ed.; Dlamini, Z., Ed.; CRC Press: Boca Raton, FL, USA, 2025; pp. 72–91.
  5. Mohammed, E.A.E.; Ali, H.M.; Farouk, W.M.; et al. Integrating Computational Approaches in Cancer Immunotherapy: Future Perspectives and Challenges. In Handbook of Cancer and Immunology, 1st ed.; Rezaei, N., Ed.; Springer: Cham, Switzerland, 2024; pp. 1–32.
  6. Anurogo, D.; Luthfiana, D.; Anripa, N.; et al. The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management. Adv. Pharm. Bull. 2024, 14, 314.
  7. Kumar, R.; Maleme, J.F.; Kumar, S.; et al. Cancer Immunotherapies: Navigating the Immune Landscape. Curr. Cancer Drug Targets 2025, in press.
  8. Wang, X.; Fan, R.; Mu, M.; et al. Harnessing Nanoengineered CAR-T Cell Strategies to Advance Solid Tumor Immunotherapy. Trends Cell Biol. 2024, in press.
  9. Barboy, O.; Katzenelenbogen, Y.; Shalita, R.; et al. In Synergy: Optimizing CAR T Development and Personalizing Patient Care Using Single-Cell Technologies. Cancer Discov. 2023, 13, 1546–1555.
  10. Lin, P.; Lin, Y.; Mai, Z.; et al. Targeting Cancer With Precision: Strategical Insights Into TCR-Engineered T Cell Therapies. Theranostics 2025, 15, 300.
  11. Garg, P.; Malhotra, J.; Kulkarni, P.; et al. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. Cancers 2024, 16, 2478.
  12. Anderson, K.G.; Braun, D.A.; Buqué, A.; et al. Leveraging Immune Resistance Archetypes in Solid Cancer to Inform Next-Generation Anticancer Therapies. J. Immunother. Cancer 2023, 11, e006533.
  13. Guan, H.; Wu, Y.; Li, L.U.; et al. Tumor Neoantigens: Novel Strategies for Application of Cancer Immunotherapy. Oncol. Res. 2023, 31, 437.
  14. Yao, L.; Wang, Q.; Ma, W. Navigating the Immune Maze: Pioneering Strategies for Unshackling Cancer Immunotherapy Resistance. Cancers 2023, 15, 5857.
  15. Weber, L. Immunotherapy in Cancer: Breakthroughs, Resistance Mechanisms, and Future Directions. Public Health Spectr. 2025, 2, e2216120.
  16. Nair, J.; Anu, J.; Sanoop, P.; et al. Impact of Nanoparticles on Immune Cells and Their Potential Applications in Cancer Immunotherapy. Biocell 2024, 48, 1579.
  17. Naffaa, M.M.; Al-Ewaidat, O.A.; Gogia, S.; et al. Neoantigen-Based Immunotherapy: Advancing Precision Medicine in Cancer and Glioblastoma Treatment Through Discovery and Innovation. Explor. Target. Anti-Tumor Ther. 2025, 6, 1002313.
  18. Marron, T.U.; Luke, J.J.; Hoffner, B.; et al. A SITC Vision: Adapting Clinical Trials to Accelerate Drug Development in Cancer Immunotherapy. J. Immunother. Cancer 2025, 13, e010760.
  19. Pongcharoen, S.; Kaewsringam, N.; Somaparn, P.; et al. Immunopeptidomics in the Cancer Immunotherapy Era. Explor. Target. Anti-Tumor Ther. 2024, 5, 801.
  20. Hudson, W.H.; Wieland, A. Technology Meets TILs: Deciphering T Cell Function in the-Omics Era. Cancer Cell 2023, 41, 41–57.
  21. Bertolaccini, L.; Casiraghi, M.; Uslenghi, C.; et al. Recent Advances in Lung Cancer Research: Unravelling the Future of Treatment. Updates Surg. 2024, 76, 2129–2140.
  22. Chen, J.; Larsson, L.; Swarbrick, A.; et al. Spatial Landscapes of Cancers: Insights and Opportunities. Nat. Rev. Clin. Oncol. 2024, 21, 660–674.
  23. Xu, S.; Wang, Q.; Ma, W. Cytokines and Soluble Mediators as Architects of Tumor Microenvironment Reprogramming in Cancer Therapy. Cytokine Growth Factor Rev. 2024, 76, 12–21.
  24. Feng, F.; Shen, J.; Qi, Q.; et al. Empowering Brain Tumor Management: Chimeric Antigen Receptor Macrophage Therapy. Theranostics 2024, 14, 5725.
  25. Addissouky, T.A.; Sayed, I.E.T.E.; Ali, M.M.; et al. Latest Advances in Hepatocellular Carcinoma Management and Prevention Through Advanced Technologies. Egypt. Liver J. 2024, 14, 2.
  26. Georgescu, M.T.; Trifanescu, O.G.; Serbanescu, G.L.; et al. Navigating a Complex Intersection: Immunotherapy and Radiotherapy Synergy in Squamous Cell Carcinoma of the Skin—A Comprehensive Literature Review. Cosmetics 2023, 10, 165.
  27. Ran, R.; Chen, X.; Yang, J.; et al. Immunotherapy in Breast Cancer: Current Landscape and Emerging Trends. Exp. Hematol. Oncol. 2025, 14, 77.
  28. Fu, W.; Wang, J.L.; Cheng, G.B.; et al. Advances in Precision Diagnosis and Treatment, and Translational Medicine Research for Refractory Relapsed Multiple Myeloma. Cancer Adv. 2025, 8, e25006.

Copyright © UK Scientific Publishing Limited.